Belgin Sever

Burdur Mehmet Akif Ersoy University

H指数:25

被引数:1,914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design, Synthesis and Biological Evaluation of Novel Oleanolic Acid Derivatives as Potential Anti-Leukemic Agents

Life-Basel

IF3.4

2026-08-150

Structural and Computationally Driven Molecule Design in Drug Discovery: Current Advances and Future Perspectives

基于结构与计算驱动的药物分子设计在药物发现中的研究进展与未来展望

Pharmaceuticals

IF4.8

2026-07-240

Discovery of a Novel 4,5-Dihydro-1H-pyrazole-1-carbothioamide Derivative with Cytotoxic, Apoptotic, and ABL1 Inhibitory Activities Against Chronic Myeloid Leukemia

发现一种具有细胞毒性、凋亡诱导和ABL1抑制活性的新型4,5-二氢-1H-吡唑-1-甲硫酮酰胺衍生物，用于治疗慢性髓性白血病

Biomedicines

IF3.9

2026-07-230

OAAI

Targeting ABL Tyrosine Kinase in Chronic Myeloid Leukemia: Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Thiazolone Derivatives

靶向慢性髓性白血病中的ABL酪氨酸激酶：新型噻唑酮衍生物的设计、合成、生物评价和计算研究

Pharmaceutics

IF5.5

2026-06-090

Hydrazonylthiazole Derivatives as Dual EGFR and ALR2 Inhibitors: Design, Synthesis, and Comprehensive In Vitro and In Silico Evaluation for Potential Anticancer Activity

肼基噻唑衍生物作为EGFR和ALR2双重抑制剂：设计、合成及潜在抗肿瘤活性的全面体外和计算机模拟评价

Pharmaceuticals

IF4.8

2026-03-040

OAAI

Design, Synthesis, and Biological Evaluation of N,N-Diphenylaniline-Based Derivatives as Antiproliferative Agents and ABL TK Inhibitors Against CML

基于N,N-二苯基苯胺衍生物的设计、合成及其作为抗增殖剂和ABL TK抑制剂的生物活性评价，用于治疗慢性粒细胞白血病（CML）。

Pharmaceuticals

IF4.8

2026-03-040

OAAI

Editorial: Emerging practices in therapeutic targeting of neurodegenerative diseases by modulating protein kinases

编者按：通过调控蛋白激酶治疗神经退行性疾病的 Emerging practices

Brain Research

IF2.6

2025-09-230

PRE

Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds

PHARMACEUTICALS

IF4.8

2025-02-191

OAAI

Editorial: Multi-targeted tyrosine kinase inhibitors in the treatment of cancer and neurodegenerative disorders

FRONTIERS IN CHEMISTRY

IF4.2

2024-07-260

OAAI

Scaffold Hopping and Structural Modification of NSC 663284: Discovery of Potent (Non)Halogenated Aminobenzoquinones

BIOMEDICINES

IF3.9

2023-12-241

OAAI

Structural Characterization of TRAF6 N-Terminal for Therapeutic Uses and Computational Studies on New Derivatives

PHARMACEUTICALS

IF4.8

2023-11-143

OAAI

Synthesis, in silico and in vitro evaluation of new 3,5-disubstituted-1,2,4-oxadiazole derivatives as carbonic anhydrase inhibitors and cytotoxic agents

JOURNAL OF MOLECULAR STRUCTURE

IF4.7

2023-03-016

PRE

Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity along with Anti-Colorectal and Anti-Breast Cancer Effects

MOLECULES

IF4.6

2022-12-223

OAAI

Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF8.5

2022-12-018

OAAI

Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2022-12-019

PRE

In Vitro Cytotoxicity Evaluation of Plastoquinone Analogues against Colorectal and Breast Cancers along with In Silico Insights

PHARMACEUTICALS

IF4.8

2022-10-1411

OAAI

Identification of New L-Heptanoylphosphatidyl Inositol Pentakisphosphate Derivatives Targeting the Interaction with HIV-1 Gag by Molecular Modelling Studies

PHARMACEUTICALS

IF4.8

2022-10-125

OAAI

Evaluation of anti-glioma effects of benzothiazoles as efficient apoptosis inducers and DNA cleaving agents

MOLECULAR AND CELLULAR BIOCHEMISTRY

IF3.7

2022-10-112

PRE

In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment

MOLECULES

IF4.6

2022-01-219

OAAI

A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy

MOLECULES

IF4.6

2022-01-136

OAAI

Belgin Sever

个人简介

教育背景

工作经历

荣誉奖项

研究方向